IBM's Legal Settlement Fails to Halt Stock Slide Ahead of Critical Earnings

IBM pays $17M to settle DOJ hiring probe as stock hits 20-year low. Analysts split ahead of Q1 earnings, with focus on AI strategy and Confluent deal.

IBM has closed a contentious legal chapter, agreeing to pay over $17 million to settle a U.S. Department of Justice probe into its hiring and compensation practices. The company, while not admitting to illegal conduct, has already adjusted or eliminated the "diversity modifiers" at the heart of the investigation. The payment is due within 14 days of last Friday's announcement. Despite drawing a line under this dispute, the news did little to stem the selling pressure on the stock, which fell 4.51% to 197.66 euros on Friday, extending its year-to-date loss to 20.51%.

This marks the company's weakest start to a year in over two decades, with the share price now trading well below its 200-day moving average of 237 euros. The legal resolution arrives just as Wall Street's attention pivots sharply to the firm's upcoming first-quarter earnings report on Wednesday, April 22, 2026.

Ahead of this key event, a clear divergence has emerged among analysts, creating a rare split in sentiment. On one side, Citigroup initiated coverage on April 10 with a bullish "Buy" rating and a $285 price target. Analyst Fatima Boolani argues the market underestimates IBM's entrenched position in complex IT environments, a moat she believes AI-native competitors cannot quickly replicate. Citi also points to the acquisitions of HashiCorp and Confluent as potential value drivers, expecting product and consulting synergies to leverage IBM's vast sales network. The firm sees a path to high-single-digit revenue growth, fueled partly by rising AI demand, and views the stock's price-to-earnings ratio of 21.1x as an attractive discount to comparable software peers.

This optimistic view is countered by a wave of caution from other institutions. Needham, Stifel, and BMO Capital have all independently lowered their price targets to $290. For Needham, this is a cut from $340; for BMO, from $350. Stifel and JPMorgan have also reduced their targets to $290 and $283, respectively, though both maintain their "Buy" and "Neutral" ratings. These analysts cite geopolitical tensions pressuring software and services revenue, unfavorable currency exchange rates, and a challenging macroeconomic backdrop as primary concerns. Stifel forecasts 2026 revenue growth of 4.5% to 5% in constant currency, slightly below the company's own 5% target, and expects a seasonally soft first quarter.

The earnings call itself is set to be a crucial test for management's strategic narrative. The early closure of the $11 billion Confluent acquisition will be a focal point, as IBM plans to integrate the data-streaming specialist into its own data platform—a cornerstone of its AI strategy. While consensus expects first-quarter results to be in line with forecasts, investors will scrutinize whether leadership can credibly defend its growth targets for AI and hybrid cloud. Specific updates on the generative AI order book, which stood at $12.5 billion at the start of the year, are also highly anticipated.

Positioning among major investors reflects this uncertainty. While some institutional players like Robeco increased their holdings last quarter, others, such as the Sumitomo Mitsui Trust Group, reduced their stakes. As the payment deadline for the legal settlement passes and the earnings date arrives, IBM faces a dual challenge: convincing the market it can navigate near-term headwinds while successfully executing on its expensive, long-term technological bets.